HER2-positive and hormone-positive together: two treatments at once

When a cancer carries both the HER2 protein and hormone receptors, it is treated for both. That usually means HER2-targeted drugs such as trastuzumab, often with chemotherapy, and hormone therapy for several years. The two treatments run partly at the same time, each blocking a different pathway the cancer uses to grow. This combination is common, and many women are in exactly this situation.

Why both treatments are needed

A cancer with both features can use either growth signal. Blocking only one leaves the other open. Treating both lowers the chance of the cancer returning more than either treatment could manage on its own, which is why oncologists plan them together from the start.

How they overlap in time

Chemotherapy and HER2 treatment usually come first. Hormone therapy is commonly started once chemotherapy ends and then runs alongside trastuzumab for the rest of its course, continuing on its own for several years after trastuzumab finishes.

When the plan may be lighter or different

Very small, node-negative cancers may be treated with a lighter chemotherapy regimen. Older women or those with other health conditions are sometimes offered HER2 treatment with hormone therapy and little or no chemotherapy, after careful discussion of the trade-offs.

Cancers that are both HER2-positive and hormone-positive generally respond well to treatment, and many women do very well over the long term. The price is a long treatment journey: about a year of HER2 treatment and several years of hormone therapy.

Response before surgery can look smaller

These cancers are somewhat less likely to disappear completely with treatment before surgery than HER2-positive cancers without hormone receptors. That does not mean the long-term outlook is worse, because hormone therapy continues working for years afterwards.

Hormone therapy needs staying power

Side effects such as hot flushes, joint pain and mood changes can make years of hormone tablets hard to keep up. Many women consider stopping at some point. Tell your team about side effects instead, because there are often ways to manage them or switch tablets.

Late recurrence is possible

Hormone-sensitive cancers can occasionally return many years later. That is one reason hormone therapy is often continued for a long period, and why follow-up should not be abandoned once you feel well.

What this page cannot tell you

It cannot tell you which drugs or how many years suit you. Ask your oncologist for a written outline of the whole plan.

The first year is busy with visits. The years that follow are quieter but need steady commitment to daily tablets and regular reviews.

Build a routine

Take hormone tablets at the same time each day, linked to something you already do, such as brushing your teeth. A weekly pill box helps you see at a glance whether a dose was taken.

Keep reporting side effects

Joint pain, hot flushes, vaginal dryness and low mood are common and often treatable. Switching from one hormone tablet to another sometimes helps when side effects become hard to live with.

Protect your bones and heart

Some hormone tablets thin the bones, and HER2 treatment needs heart monitoring. Bone density scans, exercise and good blood pressure control all support long-term health.